Literature DB >> 11489817

Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.

A Chakravarti1, M A Delaney, E Noll, P M Black, J S Loeffler, A Muzikansky, N J Dyson.   

Abstract

PURPOSE: Analysis of tumor-derived genetic lesions has provided insights into molecular pathogenesis of human gliomas. Because these changes represent only one of several mechanisms that alter gene expression during tumorigenesis, it is likely that further information will be obtained from a careful analysis of important regulatory proteins present in these tumors. EXPERIMENTAL
DESIGN: We have quantified the levels of key cell cycle/signaling proteins in 94 prospectively collected, meticulously preserved, "snap frozen" glioma specimens and have compared these levels with histopathological data and patient outcome.
RESULTS: The results of these experiments confirm that the levels of wild-type tumor suppressor proteins, such as p53, pRB, PTEN, p14(ARF), and p16(INK4), are lost or severely reduced in most gliomas, and that epidermal growth factor receptor, 2human telomerase reverse transcriptase, and cyclin-dependent kinase 4 are overexpressed frequently and with a few exceptions, almost exclusively, in glioblastomas. In addition, we report frequent underexpression of E2F-1 (in 55% of gliomas) and cyclin E overexpression (in 26% of gliomas), which have not yet been reported on the genomic level. Several of these markers significantly correlated with histopathological grade, and the levels of five proteins showed significant association with patient outcome. In particular, overexpression of epidermal growth factor receptor, human telomerase reverse transcriptase, cyclin-dependent kinase 4, and cyclin E was largely restricted to glioblastomas and was significantly associated with reduced patient survivals.
CONCLUSIONS: We conclude that the quantitation of cell cycle/signaling proteins from meticulously preserved glioma specimens provides further insights into the molecular pathogenesis of human gliomas and yields valuable prognostic information.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489817

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

Review 1.  APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1.

Authors:  Mark R Kelley; Millie M Georgiadis; Melissa L Fishel
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

2.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 3.  Impact of molecular profiling on clinical trial design for glioblastoma.

Authors:  Arnab Chakravarti; Erin Tyndall; Kamalakannan Palanichamy; Minesh Mehta; Kenneth Aldape; Jay Loeffler
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

Review 4.  Molecular profiling in glioblastoma: prelude to personalized treatment.

Authors:  Nikol Mladkova; Arnab Chakravarti
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

5.  MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a.

Authors:  Ning Wang; Heng Wei; Duo Yin; Yanming Lu; Yao Zhang; Qiao Zhang; Xiaoxin Ma; Shulan Zhang
Journal:  Tumour Biol       Date:  2015-10-28

Review 6.  Ependymomas: development of immunotherapeutic strategies.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2013-10       Impact factor: 4.618

7.  Tumor prognostic factors and the challenge of developing predictive factors.

Authors:  Emma B Holliday; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

8.  Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.

Authors:  Asa Liljegren Sundberg; Ylva Almqvist; Anna Orlova; Erik Blomquist; Holger J Jensen; Lars Gedda; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

9.  Association between EGF +61 G/A and glioma risk in a Chinese population.

Authors:  Shujie Wang; Yao Zhao; Zhenchao Ruan; Hongyan Chen; Weiwei Fan; Juxiang Chen; Qihan Wu; Ji Qian; Tianbao Zhang; Yan Huang; Daru Lu
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

Review 10.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.